Clinical Trials

Phase 1, Open-Label, Dose-Finding Study of CC-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects with Relapsed or Refractory Acute Myeloid Leukemia


Study ID
Celgene CC-90009-AML-001

NCT Number
NCT02848001 (Click on the NCT number for more information about the trial)

Research Study Number
2016-0429

Principle Investigator
Dr. Jamie Koprivnikar

Phase
I

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now